Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
11.59
+1.44 (14.19%)
At close: Jul 29, 2026, 4:00 PM EDT
11.99
+0.40 (3.45%)
Pre-market: Jul 30, 2026, 4:07 AM EDT
Anbio Biotechnology Revenue
In the year 2025, Anbio Biotechnology had annual revenue of $8.65M with 5.64% growth. Anbio Biotechnology had revenue of $4.06M in the half year ending December 31, 2025, with 11.22% growth.
Revenue (ttm)
$8.65M
Revenue Growth
+5.64%
P/S Ratio
58.83
Revenue / Employee
$320,253
Employees
27
Market Cap
508.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.65M | 461.70K | 5.64% |
| Dec 31, 2024 | 8.19M | 1.47M | 21.95% |
| Dec 31, 2023 | 6.71M | -16.83M | -71.49% |
| Dec 31, 2022 | 23.54M | 19.12M | 431.67% |
| Dec 31, 2021 | 4.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Embecta | 1.04B |
| Azenta | 596.48M |
| AngioDynamics | 320.17M |
| STAAR Surgical Company | 290.38M |
| OraSure Technologies | 113.02M |
| Sanara MedTech | 107.48M |
| Kestra Medical Technologies | 95.13M |
| Pro-Dex | 74.64M |
NNNN News
- 20 days ago - Anbio Biotechnology files automatic mixed securities shelf - TheFly
- 7 weeks ago - Anbio Biotechnology falls -22.7% - TheFly
- 4 months ago - Anbio Biotechnology Annual report: Q4 2025 - Filings
- 6 months ago - Anbio Biotechnology rises 20.0% - TheFly
- 6 months ago - Anbio Biotechnology trading resumes - TheFly
- 6 months ago - Anbio Biotechnology trading halted, volatility trading pause - TheFly
- 6 months ago - Anbio Biotechnology trading resumes - TheFly
- 6 months ago - Anbio Biotechnology trading halted, volatility trading pause - TheFly